Boothbay Fund Management LLC Cuts Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Boothbay Fund Management LLC lowered its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 53.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 87,142 shares of the company's stock after selling 100,004 shares during the quarter. Boothbay Fund Management LLC owned approximately 0.24% of Lifecore Biomedical worth $647,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of LFCR. Greenhaven Road Investment Management L.P. lifted its position in Lifecore Biomedical by 62.2% during the fourth quarter. Greenhaven Road Investment Management L.P. now owns 3,616,146 shares of the company's stock worth $26,868,000 after buying an additional 1,387,362 shares during the period. Invesco Ltd. purchased a new position in shares of Lifecore Biomedical during the 4th quarter worth about $4,128,000. DCF Advisers LLC lifted its holdings in shares of Lifecore Biomedical by 87.2% during the 4th quarter. DCF Advisers LLC now owns 539,989 shares of the company's stock worth $4,012,000 after acquiring an additional 251,511 shares during the period. 272 Capital LP boosted its position in shares of Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company's stock worth $707,000 after acquiring an additional 120,002 shares during the last quarter. Finally, Alpha Wave Global LP purchased a new stake in Lifecore Biomedical in the fourth quarter valued at approximately $866,000. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Lifecore Biomedical Trading Down 2.3 %

NASDAQ:LFCR traded down $0.16 during trading hours on Tuesday, reaching $6.86. 40,090 shares of the company were exchanged, compared to its average volume of 232,138. The firm has a market cap of $253.99 million, a price-to-earnings ratio of -12.28 and a beta of 0.65. The stock has a 50 day simple moving average of $6.32 and a 200 day simple moving average of $6.46. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, analysts predict that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.